无创产前DNA筛查与直接侵入性诊断对高危21三体妊娠流产率的影响:一项随机临床试验
该随机临床试验在法国57个中心纳入2111名早孕期联合筛查提示21三体风险介于1/5至1/250的孕妇,比较无创产前DNA(cfDNA)筛查阳性后再行侵入性检测与直接侵入性检测的策略。结果显示两组24周前流产率均为0.8%,风险差-0.03%(单侧95%CI,-0.68%至∞;cfDNA对21三体的检出率为100%(95%CI,87.2%-100%)。
要点
- 在高危孕妇中,cfDNA筛查策略未显著降低24周前流产率。
- cfDNA对21三体的检出率在本研究中为100%(95%CI,87.2%-100%)。
- 研究可能把握度不足,无法排除临床重要差异。
核心结论
- 在高危21三体妊娠孕妇中,先行cfDNA筛查、仅在阳性时行侵入性检测,与直接侵入性检测相比,未显著降低24周前流产率。
研究设计与样本
- 随机临床试验于2014年4月8日至2016年4月7日在法国57个中心开展,纳入2111名早孕期联合筛查21三体风险1/5至1/250的孕妇。
- 孕妇随机分为cfDNA筛查组(n=1034)和直接侵入性检测组(n=1017),最终分析2051名,平均年龄36.3岁(SD=5.0),1997名(97.4%)完成试验。
主要发现
- cfDNA对21三体的检出率为100%(95%CI,87.2%-100%)。
临床怎么用
- 对于早孕期联合筛查高危的孕妇,cfDNA筛查策略可作为减少不必要侵入性操作的选择,但本研究未显示其降低流产率。
局限性
- 研究可能把握度不足,无法检测流产率的临床重要差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cell-free DNA (cfDNA) tests are increasingly being offered to women in the first trimester of pregnancies at a high risk of trisomy 21 to decrease the number of required invasive fetal karyotyping procedures and their associated miscarriages. The effect of this strategy has not been evaluated. OBJECTIVE: To compare the rates of miscarriage following invasive procedures only in the case of positive cfDNA test results vs immediate invasive testing procedures (amniocentesis or chorionic villus sampling) in women with pregnancies at high risk of trisomy 21 as identified by first-trimester combined screening. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted from April 8, 2014, to April 7, 2016, in 57 centers in France among 2111 women with pregnancies with a risk of trisomy 21 between 1 in 5 and 1 in 250 following combined first-trimester screening. INTERVENTIONS: Patients were randomized to receive either cfDNA testing followed by invasive testing procedures only when cfDNA tests results were positive (n = 1034) or to receive immediate invasive testing procedures (n = 1017). The cfDNA testing was performed using an in-house validated method based on next-generation sequencing. MAIN OUTCOMES AND MEASURES: The primary outcome was number of miscarriages before 24 weeks' gestation. Secondary outcomes included cfDNA testing detection rate for trisomy 21. The primary outcome underwent 1-sided testing; secondary outcomes underwent 2-sided testing. RESULTS: Among 2051 women who were randomized and analyzed (mean age, 36.3 [SD, 5.0] years), 1997 (97.4%) completed the trial. The miscarriage rate was not significantly different between groups at 8 (0.8%) vs 8 (0.8%), for a risk difference of -0.03% (1-sided 95% CI, -0.68% to ∞; P = .47). The cfDNA detection rate for trisomy 21 was 100% (95% CI, 87.2%-100%). CONCLUSIONS AND RELEVANCE: Among women with pregnancies at high risk of trisomy 21, offering cfDNA screening, followed by invasive testing if cfDNA test results were positive, compared with invasive testing procedures alone, did not result in a significant reduction in miscarriage before 24 weeks. The study may have been underpowered to detect clinically important differences in miscarriage rates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02127515.
引用
- Malan V, Bussières L, Winer N, et al. Effect of Cell-Free DNA Screening vs Direct Invasive Diagnosis on Miscarriage Rates in Women With Pregnancies at High Risk of Trisomy 21: A Randomized Clinical Trial. JAMA. 2018. PMID: 30120476. doi:10.1001/jama.2018.9396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。